Reports Q2 revenue $954.61M, consensus $910.25M. “We delivered a strong quarter with total net product revenues growing 25% year over year led by double-digit Jakafi(R) (ruxolitinib) growth and continued momentum from Opzelura(R) (ruxolitinib) cream in atopic dermatitis and vitiligo in the United States,” said Herve Hoppenot, Chief Executive Officer, Incyte. “We continue to advance multiple programs in our pipeline, and recently announced positive topline results for two high potential programs, ruxolitinib cream in pediatric atopic dermatitis and axatilimab in chronic graft-versus-host disease.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on INCY:
- Notable companies reporting before tomorrow’s open
- Incyte, Replimune enter clinical collaboration for RP1 and INCB99280 in CSCC
- INCY Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Disney downgraded, Meta Platforms upgraded: Wall Street’s top analyst calls
- Incyte initiated with a Buy at Citi
